Loading
The largest comparison of cancer survival between countries, covering 37.5 million patients in 71 countries, found survival rising for most cancers but with very wide gaps between countries, especially for children's cancers and cancers that depend on early diagnosis and good treatment access.
CONCORD-3 analysed individual records for 37.5 million patients diagnosed with one of 18 cancers between 2000 and 2014, supplied by 322 population-based registries in 71 countries and territories, and estimated five-year net survival by country and period. Survival was rising for most cancers in most countries, including steep rises for liver and lung cancers in some countries, but international differences remained very wide. The paper documented, for example, breast cancer survival in the high 80s and 90s of percent in Australia and the United States against the mid-60s in India, and childhood brain tumour survival ranging from under 40% to over 80%.
CONCORD is the evidence base for national cancer plans and for the statement that where you live changes your chance of surviving cancer. Its country tables are the benchmark health systems use to judge early diagnosis and treatment access.
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, Cancer registries and population surveillance, Hepatocellular carcinoma.
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, Cancer registries and population surveillance, Non-small-cell lung cancer.
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, Cancer registries and population surveillance.
Shares Mortality, Cancer registries and population surveillance, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares Mortality, Cancer registries and population surveillance, Non-small-cell lung cancer.
Shares Mortality, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma, Colorectal cancer.
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, HR-positive / HER2-negative breast cancer, Colorectal cancer.
Shares Bray 2018: GLOBOCAN 2018, worldwide incidence and mortality for 36 cancers, Mortality, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.